Confidentiality For Proprietary Information Drives FDA Plan To Generate More CBD Safety Data
Executive Summary
In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."
You may also be interested in...
US House Appropriators Keep A Bullseye On FDA’s CBD Regulation Development
Appropriations subcommittee notes the funding in summary of its draft budget bill. Language on FDA’s development of CBD regulatory framework will be included in panel’s report to be released 24 hours before full committee’s markup.
‘Time Is Now’ For FDA Rule On Lawful CBD Use In Supplements, CRN Says In Citizen Petition
The trade group’s petition is second on a regulation for CBD’s use in non-drug products submitted to FDA and largely tracks with CHPA’s November 2019 petition. Comments continue to reach the FDA after in March it reopened its docket about establishing a CBD regulation, but with little data the agency says is needed for its decision.
With CBD's US Consumer Health Future In Limbo, FDA Warns About Injectable Offered OTC
With the rapid growth of CBD supplements, topicals and other consumer health products available in the US, FDA has found no shortage of businesses to warn about making noncompliant claims. Still, it previously hasn't found reason to warn CBD businesses about unsafe delivery formats.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: